Skip to main content

Market Overview

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against ICU Medical, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

Share:

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ICU Medical, Inc. ("ICU Medical" or "the Company") (NASDAQ: ICUI) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. ICU Medical announced on May 8, 2020, that it was "voluntarily recalling one single lot of Lactated Ringer's Injection, USP," admitting that "the products are being recalled to the hospital/user level due to the presence of particulate matter identified as iron oxide," and adding that "administration of a drug product that contains metal particulate matter could result in adverse events ranging from inflammation at the site of injection to more serious events that could include the formation of a blood clot obstructing the flow of blood which could lead to end-organ damage or death." Based on this news, shares of ICU Medical dropped by almost 9% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com